30th Annual Southern California Alzheimer's Disease Research Conference to be held on Friday, October 25, 2019 30 Years of Discovery: Hope on the Horizon

GIFTED BRAINS YIELD PRICELESS GAINS

Julie A. Schneider, M.D. M.S.

The Deborah R. And Edgar D. Jannotta Presidential Professor of Pathology (Neuropathology) and Neurological Sciences

Associate Director, Rush Alzheimer's Disease Center, Rush University Medical Center

What are we learning from the precious gift of brain donation from older persons?

- Alzheimer's disease pathology is often mixed with other pathologies (mixed pathology)
- Risk factors may work through increasing/decreasing pathology.
- Persons without cognitive impairment may have a lot of "subclinical" pathology
- There is pathologically unexplained cognitive change and risk factors


Auguste D & Alois Alzheimer


- First patient described 1907
 - 51 year old woman
 - Memory impairment
 - Hallucinations, delusions, paranoia
 - Agitation
 - Disorientation
- Progression over 5 years
 - At end fetal position, incontinent, unresponsive





Autopsy brain examination


- Grossly atrophic
- Microscopic exam:
 - Neuronal loss
 - Neuritic plaques
 - Neurofibrillary tangles














Alzheimer's disease

Normal brain











The Religious Orders Study

Began in 1993

- Older nuns, priests, and brothers without known dementia from across the U.S.
- All agreed to annual cognitive testing
- All agreed to brain donation at the time of death






Began in 1997


- Study with similar methods but <u>lay population</u> more reflective of general population from about 40 retirement communities and senior housing
- All agreed to annual cognitive/motor testing, blood draws
- All agreed to donate brain, spinal cord, muscle, nerve at the time of death
- F/U rates over 90% Autopsy Rates 80%

Both studies on going for 20+ years • >3,000 older persons enrolled without [known] dementia from across the USA, over 1500 autopsies

Religious Orders Study Sites




Religious Orders Study: Participating Sites

















©2003 RUSH University Medical Center



©2003 RUSH University Medical Center





©2003 RUSH University Medical Center



What are we learning from the precious gift of brain donation from older persons?


- Alzheimer's disease pathology is often mixed with other pathologies (mixed pathology)
- Risk factors may work through increasing/decreasing pathology.
- Persons without cognitive impairment may have a lot of "subclinical" pathology
- There is pathologically unexplained cognitive change and risk factors


The pathologies of the aging brain

- <u>NEURODEGENERATIVE</u>
- Alzheimer's disease (plaques/tangle)
- Lewy body disease
- TDP-43 pathology
- Hippocampal sclerosis

- VASCULAR
- Macroinfarcts (strokes)

- Microinfarcts
- CAA
- Atherosclerosis
- Arteriolosclerosis





Mixed brain pathologies common in MCI and probable AD





Fig. Pathology by clinical status proximate to death. (Blue shades) Pathologic diagnosis of Alzheimer disease (AD). Clockwise: light blue = pathologic diagnosis of AD only; dark blue = pathologic diagnosis of AD and neocortical Lewy bodies (LB); medium blue = pathologic diagnosis of AD and cerebral infarcts (I); aqua = pathologic diagnosis of AD, I, and LB. (Red shades) I and/or LB (with no pathologic diagnosis of AD). Clockwise: pink = I or LB; red = I and LB. (White) No pathologic diagnosis of AD, no I, no LB.

Schneider JA et al. Ann Neurol 2009;66:200-208.



Schneider JA et al. *Neurology* 2004;62:1148-1156.




Figure 1. Probability of dementia by Alzheimer disease pathology showing additive effects of macroscopic infarcts and microinfarcts.

Arvanitakis Z, et.al. Stroke. 2011 Mar;42(3):722-7.


Relation of Cerebral Vessel Disease to Alzheimer's Disease Dementia and Cognitive Function in Older Persons: A Crosssectional Study

Zoe Arvanitakis, MD^{1,2}, Ana W. Capuano, PhD^{1,2}, Sue E. Leurgans, PhD^{1,2}, David A. Bennett, MD^{1,2}, and Julie A. Schneider, MD^{1,2,3} А 1.0 dementia AD dementia 0.8 -74 (15%) Probability of Alzheimer's disease 105 (22%) 0.6 39(8%) 0.4 -— No infarct or vessel pathology 65 (14%) — Gross infarcts 86 (18%) Gross infarcts and microinfarcts 36 (8%) 0.2 Gross infarcts, microinfarcts, and atherosclerosis - Gross infarcts, microinfarcts, atherosclerosis, and 29 (6%) 44 (9%) arteriolosclerosis (all infarcts and vessel pathologies) 0 No significant vessel pathology Atherosclerosis only AD pathology – global score Arteriolosclerosis only В Atherosclerosis and arteriolosclerosis

Diagonal lines indicate those with infarcts

Lewy Bodies - Pathology first decribed in Parkinson's disease

Lewy body Dementia




infarcts, microinfarcts and neocortical Lewy bodies.


Schneider JA et al. Brain 2012;135:3005-3014

TDP-43 new "kid on the block" in aging and AD

ubiquinated protein in FTLD-U and ALS; 414 AA nuclear **DNA/RNA binding protein; regulates gene expression, splicing/stability of RNA transcripts**



- Related to amnestic dementia, mimics Alzheimer's Dementia
- Commonly co-occurs with AD and lowers memory
- Strongly related to cognitive decline especially memory
- Accumulation is associated with hippocampal degeneration and ultimately hippocampal sclerosis






doi:10.1093/brain/awz099

REVIEW

Limbic-predominant age-related TDP-43 encephalopathy (LATE): consensus working group report

Peter T. Nelson,¹ Dennis W. Dickson,² John Q. Trojanowski,³ Clifford R. Jack Jr.,⁴ Patricia A. Boyle,⁵ Konstantinos Arfanakis,^{5,6} Rosa Rademakers,² Irina Alafuzoff,⁷ Johannes Attems,⁸ Carol Brayne,⁹ Ian T.S. Coyle-Gilchrist,⁹ Helena C. Chui,¹⁰ David W. Fardo,¹ Margaret E. Flanagan,¹¹ Glenda Halliday,¹² Suv R.K. Hokkanen,⁹ Sally Hunter,⁹ Gregory A. Jicha,¹ Yuriko Katsumata,¹ Claudia H. Kawas,¹³ C. Dirk Keene,¹⁴ Gabor G. Kovacs,¹⁵ Walter A. Kukull,¹⁴ Allan I. Levey,¹⁶ Nazanin Makkinejad,⁶ Thomas J. Montine,¹⁷ Shigeo Murayama,¹⁸ Melissa E. Murray,² Sukriti Nag,⁵ Robert A. Rissman,¹⁹ William W. Seeley,²⁰ Reisa A. Sperling,²¹ Charles L. White III,²² Lei Yu⁵ and Julie A. Schneider⁵



The top panel shows the individual rates of global cognitive decline, adjusted for age at death, plotted by level of TDP-43 pathology, and fitted with a locally reweighted linear smooth function. The bottom panel shows the 10-year paths of global cognitive decline in typical participants with no TDP-43 pathology (solid line) and with low (long dashes, 10th percentile), moderate (short dashes, 50th percentile), or high (dotted line, 90th percentile) levels of TDP-43 pathology, adjusted for age at death, amyloid, tangles, and hippocampal sclerosis.

Box I LATE and LATE-NC summary points

- LATE-NC features
 - A sampling and staging system for routine autopsy diagnosis is proposed to characterize the anatomical distribution of TDP-43 proteinopathy
 - Stage I: amygdala only
 - Stage 2: + hippocampus
 - Stage 3: + middle frontal gyrus
 - Hippocampal sclerosis pathology may be observed (and should be reported), but is neither necessary nor sufficient for diagnosis of LATE-NC
- LATE-NC is present in >20% (up to 50%) of individuals past age 80 years according to large community-based autopsy series
- LATE is associated with substantial disease-specific cognitive impairment, usually an amnestic dementia syndrome ('dementia of the Alzheimer's type')
- The overall public health impact of LATE is on the same order of magnitude as Alzheimer's disease neuropathological changes; the diseases are often comorbid, but which pathology is more severe varies greatly between individuals
- Genetic risk factors for LATE have some overlap with FTLD-TDP and with Alzheimer's disease
- There is no molecule-specific biomarker for LATE. This is an important area of need for use in clinical trials (including as a potential exclusion criterion for Alzheimer's disease clinical trials) and longitudinal studies of the clinical and pathological progression of LATE

Wilson et al. JAMA Neurol. 2013;70(11):1418-1424


Figure 2. Odds ratios for clinical Alzheimer's-type dementia

~ 900 cases

N= 946 ROS/MAP n=398 AD dementia n= 548 no AD dementia


496 (52%) with TDP

% of mixed pathologies in clinical AD increased 60% to over 80% when considering TDP -43.



James BD, Brain. 2016 Sep 30.


Mixed pathologies published in multiple cohorts/populations/groups



Published: 20 January 2001

UPDATE ON MIXED PATHOLOGIES INCLUDING NEW FINDINGS

	NCI	MCI	Probable AD	
AD path diagnosis	42.5% 153/360	61.2% 166/271	85% 380/447	
Pure AD path dx	8.3%	7.4%	3.1%	
Mixed AD path + other Degenerative + vascular	11.67%	23.62%	47.0%	



Kapasi A et al. Acta Neuropathologica 2017

Published in final edited form as: Ann Neurol. 2018 January ; 83(1): 74-83. doi:10.1002/ana.25123.

Person-specific contribution of neuropathologies to cognitive loss in old age

Patricia A. Boyle^{1,2}, Lei Yu^{1,3}, Robert S. Wilson^{1,2,3}, Sue E. Leurgans^{1,3}, Julie A. Schneider^{1,3,4}, and David A. Bennett^{1,3} ¹Rush Alzheimer's Disease Center, Rush University Medical Center, Chicago, IL, USA

- AD most common pathology (65%)
- But AD occurred alone < 9%
- AD, TDP-43, and CAA most commonly co-morbid but depending on specific combination present in between 22 and 41 persons
- More than 230 combinations of pathology –
- most combinations in less than 20 persons

Top 10 most specific combinations of pathology

1. AD only;n=64; 5.9%

2. none of the 9; n=62; 5.8%

3. AD and CAA, n=41; 3.8%

4. AD +CAA+TDP, n=26; 2.4%

5. Gross infarcts, n=24; 2.2%

6. Atherosclerosis, n=22, 2.0%

7. AD +TDP, n= 18, 1.7%

8. TDP43, n= 17; 1.6%

9. AD + atherosclerosis, n=17; 1.6%,

10. Microinfarcts, n=16; 1.5%

236 combinations of pathology!

How much dementia could be averted by eliminating specific groups of pathology?

(Using logistic regression models that include age and pathologies with dementia as outcome)

Ann Neurol. 2019 Jan;85(1):114-124. doi: 10.1002/ana.25380. Epub 2018 Dec 19.

Attributable risk of Alzheimer's dementia attributed to age-related neuropathologies.

Boyle PA^{1,2}, Yu L^{1,3}, Leurgans SE^{1,3}, Wilson RS^{1,2,3}, Brookmeyer R⁴, Schneider JA^{1,3,5}, Bennett DA^{1,3}.

Author information

1 Rush Alzheimer's Disease Center, Rush University Medical Center, Chicago, IL.

Pathologic AD - fraction averted 52%*


Lewy bodies, HS, and TDP......36.8%

Infarcts, CAA, athero-, arteriolosclerosis......46.8%

* Cohort specific estimates/ not accounting for other pathologies

** Note numbers do not add up to 100 since there is inter-relationships between pathologies.

	Characteristic	Total (n=804)	Age 65-89	Age 90 +	P value
Pathology and dementia in the oldest old (age 90+ vs. <90)			(n=503)	(n = 301)	
	Age at death, yrs(SD)	87.7 (6.7)	83.8 (4.8)	94.3 (3.3)	<0.001
	Dementiaª, no. (%)	304 (37.8%)	143 (28.4%)	161 (53.5%)	<0.001
	AD ^c	493 (61.3%)	279 (55.5%)	214 (71.1%)	< 0.001
James BD et al., JAMA. 2012 May 2;307(17):1798- 800.	Infarcts ^d	272 (33.8%)	147 (29.2%)	125 (41.5%)	< 0.001
	Single path	374 (46.5%)	238 (47.3%)	136 (45.2%)	0.56
	Mixed path	225 (28.0%)	113 (22.5%)	112 (37.2%)	<0.001
	AD + LB	41 (5.1%)	25 (5.0%)	16 (5.3%)	0.83
	AD + Infarcts	162 (20.2%	79 (15.7%)	83 (27.6%)	<0.001



Barnes LL et al. Neurology 2015

What are we learning from the precious gift of brain donation from older persons?

- Alzheimer's disease pathology is often mixed with other pathologies (mixed pathology)
- Risk factors may work through increasing/decreasing pathology.
- Persons without cognitive impairment may have a lot of "subclinical" pathology
- There is pathologically unexplained cognitive change and risk factors

Multiple Potential Pathways to Dementia

*Misfolded proteins

amyloid

Lifestyle Factors physical activity diet drug/alcohol abuse **Environmental Factors** education head trauma toxins/other **Psychosocial Factors** depression/anxiety Aging **Genetic Factors** Sex F>M **Other Medical Risks** hypertension obesity stroke heart disease diabetes metabolic inflammation certain infectious diseases certain medications **Health Disparities Factors**

tau alpha synuclein **TDP-43** *Vascular Disorders infarct (stroke) white matter disease blood vessel disease *Other Disorders **BRAIN CHANGES**

Cognitive Impairment Including Dementia


Alzheimer's Dementia Lewy Body Dementias Vascular Dementias Frontotemporal Dementias Limbic Predominant TDP Mixed Dementias Other Cognitive Impairment Other Dementias

Concept by: Julie A. Schneider, MD, MS, Rush University & Roderick A. Corriveau, PhD, NINDS



ARTICLE

Late-life blood pressure association with cerebrovascular and Alzheimer disease pathology




Published in final edited form as: Alzheimers Dement. 2015 January; 11(1): 32–39. doi:10.1016/j.jalz.2013.12.015.

Brain Tocopherols Related to Alzheimer Disease Neuropathology in Humans

Martha Clare Morris, Sc.D.¹, Julie A Schneider, MD, MPH^{2,3}, Hong Li, MS¹, Christy C Tangney, PhD⁴, Sukrit Nag, MD^{2,3}, David A Bennett, MD², William G. Honer, MD⁵, and Lisa Barnes, PhD²

Martha Clare Morris: Martha_C_Morris@rush.edu; Julie A Schneider: Julie 76@gmail.com; Christy C Tangney: Christy_Tangney@rush.edu; Sukrit Na David_A_Bennett@rush.edu; William G. Honer: honer@mail.ubc.ca; Lisa E

Vitamin E in the brain related to more vs. less amyloid depending on the type of tocopherol!



SUDRE. AUUIOL Manuscript, available III FING 2010 Apr 1.

Published in final edited form as:

<u>Stroke. 2015 Apr; 46(4): 1071–1076.</u> doi: 10.1161/STROKEAHA.114.008010 NIHMSID: NIHMS663731 PMID: 25791714

Purpose in Life and Cerebral Infarcts in Community Dwelling Older Persons

Lei Yu, PhD,^{1,2} Patricia A. Boy MD,^{1,2,6} and David A. Bennett,

Author information
Copy

<u>Stroke</u>. Author manuscript; available in PMC 2017 Feb 1. Published in final edited form as: <u>Stroke. 2016 Feb; 47(2): 516–518.</u> Published online 2016 Jan 14. doi: 10.1161/STROKEAHA.115.011608

PMCID: PMC4780848 NIHMSID: NIHMS740250 PMID: 26768207

Sleep Fragmentation, Cerebral Arteriolosclerosis, and Brain Infarct Pathology in Community-Dwelling Older People

Andrew S.P. Lim, MD,^{1,*} Lei Yu, PhD,² Julie A. Schneider, MD,^{2,3} David A. Bennett, MD,² and Aron S. Buchman,

MD²



HHS Public Access

Author manuscript *JAMA*. Author manuscript; available in PMC 2017 June 06.

Published in final edited form as:

JAMA. 2016 February 02; 315(5): 489-497. doi:10.1001/jama.2015.19451.


Association of Seafood Consumption, Brain Mercury Level, and APOE e4 Status With Brain Neuropathology in Older Adults

Martha Clare Morris, ScD, Section on Nutrition and Nutritional Epidemiology, Department of Internal Medicine, Rush

What are we learning from the precious gift of brain donation from older persons?

- Alzheimer's pathology often mixed with other pathologies (mixed pathology)
- Risk factors and genetics may work through increasing pathology, resilience or unknown mechanisms.
- Persons <u>without cognitive impairment</u> may have a lot of subclinical pathology (resilience)
- There is a lot we still don't know about the brain changes of cognitive decline in aging.

Pathology in those without MCI or dementia



Pathology without cognitive impairment...

Lesser amounts of pathology

A

? Better repair mechanisms

? Less or "better" inflammation

? Compensation via other pathways

Published in final edited form as: Neurology. 2006 November 14; 67(9): 1581–1585. doi:10.1212/01.wnl.0000242734.16663.09.

Memory complaints are related to Alzheimer disease pathology in

older persons

L.L. Barnes, PhD, J.A. Schneider, MD, P.A. Boyle, PhD, J.L. Bienias, ScD, and D.A. Bennett, MD Rush Alzheimer's Disease Center (L.L.B., J.A.S., P.A.B., D.A.B.) and Rush Institute for Healthy Aging (J.L.B.) and Departments of Neurological Sciences (L.L.B., J.A.S., D.A.B.), Internal Medicine

(J.L.B.), and Behavioral Sciences (L.L.B., P.A.B.), Rush University Medical Center, Chicago, IL.

Published in final edited form as: *Ann Neurol.* 2018 April; 83(4): 718–729. doi:10.1002/ana.25189.

Memory Complaints, Dementia, and Neuropathology in Older Blacks and Whites

Zoe Arvanitakis, MD, MS^{a,b}, Sue E. Leurgans, PhD^{a,b}, Debra A. Fleischman, PhD^{a,b,c}, Julie A. Schneider, MD, MS^{a,b,d}, Kumar B. Rajan, PhD^e, Jeremy J. Pruzin, MD^{a,b}, Raj C. Shah, MD^{a,f}, Denis A. Evans, MD^e, Lisa L. Barnes, PhD^{a,b,c}, and David A. Bennett, MD^{a,b}

Ann N Y Acad Sci. 2009 Jul;1170:730-5. doi: 10.1111/j.1749-6632.2009.04013.x.

Olfactory impairment in presymptomatic Alzheimer's disease.

Wilson RS¹, Arnold SE, Schneider JA, Boyle PA, Buchman AS, Bennett DA.

J Elder Abuse Negl. Author manuscript; available in PMC 2015 Jan 1.

Published in final edited form as:

J Elder Abuse Negl. 2014; 26(2): 107-122.

doi: 10.1080/08946566.2013.821809

PMCID: PMC3916958 NIHMSID: NIHMS509695 PMID: <u>24499279</u>

Correlates of Susceptibility to Scams in Older Adults Without Dementia

Bryan D. James, PhD, Assistant professor,^{1,2} Patricia A. Boyle, PhD, Associate professor,^{1,3} and David A. Bennett, MD, Professor and Director^{1,4}

Ann Intern Med. 2019 May 21;170(10):702-709. doi: 10.7326/M18-2711. Epub 2019 Apr 16.

Scam Awareness Related to Incident Alzheimer Dementia and Mild Cognitive Impairment: A Prospective Cohort Study.

Boyle PA¹, Yu L¹, Schneider JA¹, Wilson RS¹, Bennett DA¹.

Author information

1 Rush Alzheimer's Disease Center, Rush University Medical Center, Chicago, Illinois (P.A.B., L.Y., J.A.S., R.S.W., D.A.B.).

. . .



HEALTH


ALZHEIMER'S EARLY WARNING: FALLING FOR SCAMS COULD BE SIGN OF DEMENTIA

BY KASHMIRA GANDER ON 4/15/19 AT 5:00 PM EDT

② APRIL 16, 2019

Senior's weakness for scams may be warning sign of dementia

by Lauran Neergaard



In this May 19, 2015, file photo, a doctor points to PET scan results that are part of a study o...


Does an older friend or relative have a hard time hanging up on telemarketers? Or get excited about a "You've won a prize" voicemail? New research suggests seniors who aren't on guard against scams also might be at risk for eventually developing Alzheimer's disease.

What are we learning from the precious gift of brain donation from older persons?

- Alzheimer's pathology often mixed with other pathologies (mixed pathology)
- Risk factors and genetics may work through increasing pathology, resilience or unknown mechanisms.
- Persons <u>without cognitive impairment</u> may have a lot of subclinical pathology (resilience)
- There is a lot we still don't know about the brain changes of cognitive decline in aging.







Published in final edited form as: *Ann Neurol.* 2013 September ; 74(3): . doi:10.1002/ana.23964.

Much of late life cognitive decline is not due to common neurodegenerative pathologies

Patricia A. Boyle, PhD^{1,2}, Robert S. Wilson, PhD^{1,2,3}, Lei Yu, PhD^{1,3}, Alasdair M Barr, PhD⁴, William G. Honer, M.D.⁵, Julie A. Schneider, MD^{1,3,6}, and David A. Bennett, MD^{1,3} ¹Rush Alzheimer's Disease Center, Rush University Medical Center




Figure 3.

Variation in cognitive decline explained by the pathologic indices (grey) and the residual, unexplained variation in cognitive decline (white) derived from fully adjusted models. Published in final edited form as: Neuropsychology. 2016 February ; 30(2): 135–142. doi:10.1037/neu0000223.

Late-Life Depression is Not Associated with Dementia Related Pathology

Robert S. Wilson, PhD, Patricia A. Boyle, PhD, Ana W. Capuano, PhD, Raj C. Shah, MD, George M. Hoganson, MD, Sukriti Nag, MD, PhD, and David A. Bennett, MD Rush University Medical Center

J Affect Disord. 2019 May 1;250:313-318. doi: 10.1016/j.jad.2019.03.051. Epub 2019 Mar 8.

Brain IGFBP-5 modifies the relation of depressive symptoms to decline in cognition in older persons.

Capuano AW¹, Wilson RS², Honer WG³, Petyuk VA⁴, Leurgans SE⁵, Yu L⁵, Gatchel JR⁶, Arnold S⁷, Bennett DA⁵, Arvanitakis Z⁵.

Author information

1 Rush Alzheimer's Disease Center, Rush University Medical Center, Chicago, IL, USA; Department of Neurological Sciences, Rush University Medical Center, Chicago, IL, USA. Electronic address: ana_capuano@rush.edu. Published in final edited form as: Am J Geriatr Psychiatry. 2011 April; 19(4): 327–334. doi:10.1097/JGP.0b013e31820119da.

Vulnerability to Stress, Anxiety, and Development of Dementia in Old Age

Robert S. Wilson, PhD, Christopher T. Begeny, BA, Patricia A. Boyle, PhD, Julie A. Schneider, MD, and David A. Bennett, MD

Rush Alzheimer's Disease Center and Departments of Neurological Sciences (RSW, JAS, DAB), Behavioral Sciences (RSW, PAB), and Pathology (JAS), Rush University Medical Center, Chicago, IL, USA

> Published in final edited form as: Neurobiol Aging. 2013 April ; 34(4): 1045–1050. doi:10.1016/j.neurobiolaging.2012.08.008.

Personality and resilience to Alzheimer's disease neuropathology: A prospective autopsy study

Antonio Terracciano, PhD^{1,4,*}, Diego Iacono, MD PhD^{2,5,*}, Richard J O'Brien, MD PhD³, Juan C Troncoso, MD^{2,3}, Yang An, MS¹, Angelina R Sutin, PhD^{1,4}, Luigi Ferrucci, MD PhD¹, Alan B Zonderman, PhD¹, and Susan M Resnick, PhD¹

¹National Institute on Aging, National Institutes of Health

²Division of Neuropathology, Johns Hopkins University

³Department of Neurology, Johns Hopkins University

⁴College of Medicine, Florida State University, Tallahassee, FL, USA

⁵The Brain Bank at Karolinska Institutet, Department of Neurobiology, Care Sciences and Society (NVS), Stockolm, Sweden.



HHS Public Access

Author manuscript *JAMA*. Author manuscript; available in PMC 2017 June 06.

Published in final edited form as: JAMA. 2016 February 02; 315(5): 489–497. doi:10.1001/jama.2015.19451.

Association of Seafood Consumption, Brain Mercury Level, and APOE e4 Status With Brain Neuropathology in Older Adults



Martha Clare Morris, ScD,

Section on Nutrition and Nutritional Epidemiology, Department of Internal Medicine, Rush University Medical Center, Chicago, Illinois



HHS Public Access

Author manuscript Mol Psychiatry. Author manuscript; available in PMC 2019 August 18.

Brain iron is associated with accelerated cognitive decline in people with Alzheimer pathology

Scott Ayton¹, Yamin Wang², Ibrahima Diouf^{1,3}, Julie A Schneider⁴, John Brockman⁵, Martha Clare Morris^{2,*,#}, Ashley I. Bush^{1,*,#}

¹Melbourne Dementia Research Centre, Florey Institute of Neuroscience and Mental Health, and The University of Melbourne, Parkville, Australia

²Rush Institute for Healthy Aging, Rush University Medical Center, Chicago, USA

³CSIRO Health and Biosecurity, Australian E-Health Research Centre, Brisbane, Australia

⁴Rush Alzheimer Disease Center, Rush University Medical Center, Chicago, USA

⁵Missouri University Research Reactor, Columbia (Brockman), USA

ARTICLE


Cognitive decline after elective and nonelective hospitalizations in older adults

Bryan D. James, PhD, Robert S. Wilson, PhD, Ana W. Capuano, PhD, Patricia A. Boyle, PhD, Raj C. Shah, MD, Melissa Lamar, PhD, E. Wesley Ely, MD, David A. Bennett, MD, and Julie A. Schneider, MD

Neurology[®] 2019;92:1-10. doi:10.1212/WNL.00000000006918

Correspondence Dr. James Bryan_James@rush.edu

Figure 2 Rate of decline in global cognition in those who had hospitalization (before and after) or no hospitalization



Conclusions

- Alzheimer's dementia is a complex brain disease with many potential therapeutic targets.
- There are a multitude of risk and protective factors. A better understanding of these is important. For now vascular risk factors important to control.
- Persons without cognitive impairment may have a lot of "subclinical" pathology. Important to recognize but also opportunity for prevention/treatment.
- Pathologically unexplained cognitive change and related risk factors also an opportunity for new prevention and treatment strategies.

Acknowledgments

Rush Alzheimer's Disease Center

Neelum Aggarwal, MD Konstantinos Arfanakis, PhD Zoe Arvanitakis, MD Lisa Barnes, PhD David Bennett, MD Patricia Boyle, PhD Aron Buchman, MD Ana Capuano, PhD Robert Dawe, PhD Debra Fleischman, PhD Chris Gaiteri, PhD Crystal Glover, PhD Jeff Hausdorf, PhD Bryan James, PhD Alifiya Kapasi PhD Namhee Kim, PhD Melissa Lamar PhD Sue Leurgans, PhD Sukriti Nag, MD, PhD Shahram Oveisgharan, MD Raj Shah, MD Shinya Tasaki, PhD Jingyun Yang, PhD Lei Yu, PhD Robert Wilson, PhD

- NIH including NIA, NINDS
- Alzheimer's Association
- The Deborah R. And Edgar D. Jannotta Presidential Endowment Fund
- Elsie Heller Brain Bank Endowment Fund
- Robert C. Borwell Endowment Fund
- Study Participants, ROS, Rush Memory and Aging Project, Minority Aging Research Study
- Rush ADC Center Staff
- Rush ADC Laboratory
 - Karen Skish
 - Ryan Johnson
 - Srabani Mondal

THANK YOU!